Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the R&D spend buried in a 300-page report or tracing how device recalls affect margins can slow any analysis. Dentsply Sirona SEC filings explained simply is exactly what busy investors need.
Our platform ingests every Dentsply Sirona annual report 10-K simplified, Dentsply Sirona quarterly earnings report 10-Q filing, and surprise notice so you see the essentials first. Stock Titan’s AI highlights which product lines—consumables, CAD/CAM, or imaging—drove revenue shifts, and flags any Dentsply Sirona 8-K material events explained within minutes of hitting EDGAR. Need deeper context? Click for a concise Dentsply Sirona earnings report filing analysis that breaks out geographic sales and regulatory commentary.
Monitoring management moves is just as seamless. Receive alerts on Dentsply Sirona insider trading Form 4 transactions and watch Dentsply Sirona Form 4 insider transactions real-time to spot buying or selling patterns before the market reacts. Our dashboards also chart Dentsply Sirona executive stock transactions Form 4 against upcoming product launches, while the latest Dentsply Sirona proxy statement executive compensation is distilled into clear compensation ratios.
Whether you’re understanding Dentsply Sirona SEC documents with AI for a valuation model or verifying compliance disclosures, Stock Titan delivers every filing type—10-K, 10-Q, 8-K, S-8, DEF 14A—backed by AI-powered summaries, keyword search, and real-time updates. Spend less time parsing, and more time deciding.
DENTSPLY SIRONA insider Daniel T. Scavilla, who serves as President, CEO and director, reported transactions dated 08/08/2025. The filing shows a disposition of 17,475.049 shares of common stock and the acquisition of 1,102,600 stock options with an exercise price of $12.96. The options are exercisable beginning 08/08/2026 and expire 08/08/2035. The grant vests in three equal annual installments, ending 08/08/2028, and is recorded with a price of $0. Ownership of the reported derivative and the disposal are shown as direct. No additional financial metrics or compensatory values are provided in the form.
Gregory T. Lucier, a director of DENTSPLY SIRONA Inc. (XRAY), reported equity awards and transfers dated 08/08/2025. The filing shows a grant of 3,858 restricted stock units (RSUs) that vest in full one year from the grant date, and a separate transfer/gift of 24,047 RSUs to a family partnership in which the reporting person disclaims beneficial ownership except for any pecuniary interest.
The report also shows an indirect holding of 21,000 shares held in the reporting person's IRA and a grant of 17,200 stock options with an exercise price of $12.96, vesting in one year and expiring on 08/08/2035. The form includes post-transaction beneficial ownership figures for the reporting person and related accounts as provided in the filing.
Andrea L. Frohning, Senior Vice President and CHRO of DENTSPLY SIRONA Inc. (ticker XRAY), reported a transaction on 08/08/2025 on Form 4. The filing shows 788 shares of common stock were withheld to cover taxes related to the vesting of restricted stock units and dividend equivalent units previously reported. The transaction is reported with code F and a price of $12.96 per share.
After the withholding, the beneficial ownership reported for Ms. Frohning is 33,252.812 shares, held directly. The Form identifies the reporting person and the issuer but does not disclose any open-market purchases or sales separate from the tax-withholding event.
FAQ
What is the current stock price of Dentsply Sirona (XRAY)?
What is the market cap of Dentsply Sirona (XRAY)?
